Universität zu Köln

Reuter, Katrin, Albrecht, Karoline, Seelig, Harald ORCID: 0000-0002-2178-4807, Meiss, Frank, Mauch, Cornelia, Kreuzberg, Nicole and Nashan, Dorothee (2014). Health-related Quality of Life, Fatigue, and Depression Under Low-Dose. IEN-alpha Therapy in Melanoma Patients. J. Immunother., 37 (9). S. 461 - 468. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1537-4513

Full text not available from this repository.

Abstract

Adjuvant melanoma treatment with interferon-alpha (IFN-alpha) has proven to be accompanied by several side effects and to decrease patients' health-related quality of life (HROOL), fatigue and depression being essential factors at that. Although a large body of evidence exists for HRQOL under IFN-alpha therapy, we now specifically address this topic combining the HRQOL survey in the first months of IFN-alpha low-dose treatment with a structured assessment of relevant neuropsychiatric side effects, fatigue and depression, with specific validated assessment tools. The present study is a longitudinal observational study assessing fatigue, depression, and HRQOL with specific assessment tools at 3 assessment points over 6 months. The IFN-alpha treatment group consisted of 48 patients with current IFN-alpha therapy (3 MU 3 times weekly) from a consecutively recruited melanoma collective and compared with a parallelized nontreatment group (n = 48) in routine clinical practice. A descriptive analysis and generalized linear models were applied to compare the groups. Physical fatigue increased significantly within the first months of IFN-alpha treatment, whereas cognitive and emotional fatigue and depression symptoms did not show this increase. The hypothesis of a significant deterioration of HRQOL after IFN-alpha initiation was not confirmed. The treatment group did, however, show a different course of global HRQOL than the comparison group, with a significant improvement in the nontreatment group. Patients under low-dose IFN-alpha therapy primarily suffer from physical side effects, mainly physical fatigue, in the early phases of treatment. The HRQOL improvement evident in the nontreatment group was not observed in the IFN-alpha group.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Reuter, Katrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Albrecht, Karoline UNSPECIFIED UNSPECIFIED UNSPECIFIED Seelig, Harald UNSPECIFIED orcid.org/0000-0002-2178-4807 UNSPECIFIED Meiss, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Mauch, Cornelia UNSPECIFIED UNSPECIFIED UNSPECIFIED Kreuzberg, Nicole UNSPECIFIED UNSPECIFIED UNSPECIFIED Nashan, Dorothee UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-424908
DOI:	10.1097/CJI.0000000000000057
Journal or Publication Title:	J. Immunother.
Volume:	37
Number:	9
Page Range:	S. 461 - 468
Date:	2014
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
Place of Publication:	PHILADELPHIA
ISSN:	1537-4513
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTERFERON-ALPHA; PEGYLATED INTERFERON-ALPHA-2B; MALIGNANT-MELANOMA; HOSPITAL ANXIETY; EUROPEAN-ORGANIZATION; ADJUVANT THERAPY; SYMPTOMS; TRIAL; CANCER; PHASE Multiple languages Oncology; Immunology; Medicine, Research & Experimental Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/42490